Marex Group plc Takes $10.42 Million Position in Sana Biotechnology, Inc. $SANA

Marex Group plc purchased a new stake in shares of Sana Biotechnology, Inc. (NASDAQ:SANA) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 3,817,780 shares of the company’s stock, valued at approximately $10,423,000. Marex Group plc owned approximately 1.61% of Sana Biotechnology at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. Corient Private Wealth LLC raised its holdings in Sana Biotechnology by 264.7% during the 2nd quarter. Corient Private Wealth LLC now owns 1,136,000 shares of the company’s stock valued at $3,101,000 after acquiring an additional 824,505 shares during the period. Captrust Financial Advisors grew its position in shares of Sana Biotechnology by 43.8% in the second quarter. Captrust Financial Advisors now owns 15,793 shares of the company’s stock valued at $43,000 after purchasing an additional 4,807 shares in the last quarter. BNP Paribas Financial Markets raised its stake in shares of Sana Biotechnology by 46.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 15,444 shares of the company’s stock valued at $42,000 after purchasing an additional 4,931 shares during the period. Brevan Howard Capital Management LP lifted its holdings in Sana Biotechnology by 85.3% during the 2nd quarter. Brevan Howard Capital Management LP now owns 260,723 shares of the company’s stock worth $712,000 after purchasing an additional 120,016 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. bought a new position in Sana Biotechnology in the 2nd quarter worth about $1,916,000. 88.23% of the stock is currently owned by hedge funds and other institutional investors.

Sana Biotechnology Price Performance

SANA stock opened at $5.14 on Friday. The firm has a 50 day simple moving average of $4.50 and a two-hundred day simple moving average of $3.76. The stock has a market cap of $1.37 billion, a PE ratio of -5.30 and a beta of 1.95. Sana Biotechnology, Inc. has a one year low of $1.26 and a one year high of $7.30.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.03. On average, research analysts expect that Sana Biotechnology, Inc. will post -1.16 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sana Biotechnology in a research report on Monday, December 8th. Citizens Jmp boosted their price objective on shares of Sana Biotechnology from $5.00 to $8.00 and gave the company a “market outperform” rating in a research note on Thursday, October 30th. Wall Street Zen cut shares of Sana Biotechnology from a “hold” rating to a “sell” rating in a research note on Saturday, November 22nd. Wedbush raised their price target on shares of Sana Biotechnology from $5.00 to $6.00 and gave the company an “outperform” rating in a report on Friday, November 7th. Finally, HC Wainwright decreased their price target on shares of Sana Biotechnology from $11.00 to $9.00 and set a “buy” rating on the stock in a report on Friday, November 7th. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $8.33.

Sana Biotechnology Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.